Business Description
Curanex Pharmaceuticals Inc
NAICS : 541715
SIC : 2834
ISIN : US23126K1060
Total Employee Number:
6Description
Curanex Pharmaceuticals Inc is engaged in discovering, developing, and commercializing botanical drugs for treating unmet medical needs in patients with inflammatory disease. Its compound, Phyto-N, is in preclinical research for six indications: ulcerative colitis, atopic dermatitis, COVID-19, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and gout. Phyto-N, is a proprietary botanical extract with chemical components and pharmacological activities that harnesses potential anti-inflammatory properties of a medicinal plant.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 12.92 | |||||
Equity-to-Asset | 0.96 | |||||
Debt-to-Equity | 0.04 | |||||
Debt-to-EBITDA | -0.04 | |||||
Piotroski F-Score | N/A/9 | |||||
WACC vs ROIC | ||||||
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 60.34 | |||||
9-Day RSI | 47.18 | |||||
14-Day RSI | 40.85 | |||||
3-1 Month Momentum % | -36.4 | |||||
6-1 Month Momentum % | -18.1 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 62.74 | |||||
Quick Ratio | 62.74 | |||||
Cash Ratio | 31.16 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.7 | |||||
Shareholder Yield % | -0.12 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -105.62 | |||||
ROA % | -100.39 | |||||
ROIC % | -176.68 | |||||
3-Year ROIIC % | -64.07 | |||||
ROC (Joel Greenblatt) % | -175.33 | |||||
ROCE % | -102.34 | |||||
Moat Score | 3 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 0.72 | |||||
Price-to-Tangible-Book | 0.71 | |||||
EV-to-EBIT | -0.29 | |||||
EV-to-EBITDA | -0.3 | |||||
EV-to-FCF | -0.19 | |||||
| Price-to-Net-Current-Asset-Value | 0.76 | |||||
| Price-to-Net-Cash | 1.58 | |||||
Earnings Yield (Greenblatt) % | -344.83 | |||||
FCF Yield % | -193.97 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CURX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Curanex Pharmaceuticals Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.272 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | - | ||
| 14-Day RSI | 40.85 | ||
| 14-Day ATR ($) | 0.022695 | ||
| 20-Day SMA ($) | 0.206465 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range ($) | 0.1788 - 9.1796 | ||
| Shares Outstanding (Mil) | 28.36 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Curanex Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Curanex Pharmaceuticals Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-30 | In 121 days | ||
| Second quarter earnings results for 2026 | 2026-08-31 | In 30 days | ||
| General meeting for 2026 | 2026-08-17 | In 16 days | ||
| First quarter earnings results for 2026 | 2026-05-14 | 0.32 (-1.50%) | ||
| Annual report for 2025 | 2026-03-30 | 0.48 (-5.04%) |
Show
Entries
Curanex Pharmaceuticals Inc Frequently Asked Questions
What is Curanex Pharmaceuticals Inc(CURX)'s stock price today?
The current price of CURX is $0.21. The 52 week high of CURX is $9.18 and 52 week low is $0.18.
When is next earnings date of Curanex Pharmaceuticals Inc(CURX)?
The next earnings date of Curanex Pharmaceuticals Inc(CURX) is 2026-08-31 Est..
Does Curanex Pharmaceuticals Inc(CURX) pay dividends? If so, how much?
Curanex Pharmaceuticals Inc(CURX) does not pay dividend.
Guru Commentaries on NAS:CURX
No articles.
Press Release
Articles on Curanex Pharmaceuticals Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers